Hledání v detailu akcií
Top akcie
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,53
KB-0,11
PKN81,1281,7-1,05
Msft-0,49
Nokia5,0025,006-0,16
IBM-0,30
Daimler AG57,2257,24-0,30
PFE-0,40
17.7.2018 1:38:50
Indexy online
AD Index online
select
AD Index online
 

  • 16.7.2018
Cara Therapeutics (NASDAQ Cons)
Závěr k 16.7.2018 Změna (%) Změna (USD) Objem obchodů (ks)
21,16 -2,58 -0,56 764 299
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 17.7.2018
Popis společnosti
Obecné informace
Název společnostiCara Therapeutics Inc
TickerCARA
Kmenové akcie:Ordinary Shares
RICCARA.O
ISINUS1407551092
Prioritní akcieConv. Pref. Shrs
Poslední známé roční výsledky31.12.2017
Poslední známé čtvrtletní výsledky31.3.2018
Počet zaměstnanců k 31.12.2017 37
Akcie v oběhu k 3.5.2018 32 699 943
Počet akcionářů k 31.12.2017 39
MěnaUSD
Kontaktní informace
Ulice4 Stamford Plz
MěstoSTAMFORD
PSČ06902-3834
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon12 034 063 700
Fax12035671510

Business Summary: Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body's peripheral nervous system. The Company operates through the activities related to the discovery and development of therapeutics to treat serious medical conditions, including pain and pruritus. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain. I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. CR845 has exhibited anti-pruritic, or anti-itch, potency in standard preclinical models.
Financial Summary: BRIEF: For the three months ended 31 March 2018, Cara Therapeutics Inc revenues decreased from $911K to $0K. Net loss decreased 24% to $16.8M. Revenues reflect License and milestone fees decrease from $530K to $0K, Collaborative revenue decrease from $313K to $0K, Clinical compound revenue decrease from $68K to $0K. Lower net loss reflects Research and development - Balancing v decrease of 37% to $12.7M (expense).
Odvětvová klasifikace
TRBC2012Biotechnology & Medical Research - NEC
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
SICPharmaceutical Preparations



  • Poslední aktualizace: 17.7.2018
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorDennis Glass676.7.20073.4.2006
Chief Financial Officer, Executive Vice PresidentRandal Freitag541.1.20111.1.2011
President of Lincoln Financial Group DistributionWilford Fuller4610.10.201213.2.2009
Chief Human Resource Officer, Executive Vice PresidentLisa Buckingham511.12.2008
Executive Vice President, Chief Investment OfficerEllen Cooper526.8.20126.8.2012
Executive Vice President, Chief Information Officer, Head of Administrative ServicesKenneth Solon56
Executive Vice President, General CounselKirkland Hicks45
Senior Vice President, Chief Ethics and Compliance OfficerSteve Harris-17.4.201717.4.2017
Senior Vice President, Corporate SecretaryAndrea Goodrich-17.1.201717.1.2017
Senior Vice President - Head of OperationsMolly Garrett-10.8.201710.8.2017